Cencora (NYSE:COR) Issues FY 2026 Earnings Guidance

Cencora (NYSE:COR) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 17.650-17.900 for the period, compared to the consensus estimate of 17.600. The company issued revenue guidance of $334.2 billion-$340.6 billion, compared to the consensus revenue estimate of $345.9 billion.

Cencora Price Performance

Shares of Cencora stock traded down $52.71 during midday trading on Wednesday, hitting $253.20. 6,440,815 shares of the company traded hands, compared to its average volume of 1,399,540. The firm’s fifty day moving average price is $332.27 and its 200-day moving average price is $343.21. The stock has a market cap of $49.25 billion, a price-to-earnings ratio of 30.43, a PEG ratio of 1.42 and a beta of 0.64. Cencora has a 12 month low of $244.82 and a 12 month high of $377.54. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts’ consensus estimates of $4.80 by ($0.05). The company had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The business’s quarterly revenue was up 3.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, sell-side analysts forecast that Cencora will post 17.58 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently commented on COR. Jefferies Financial Group upgraded shares of Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Leerink Partners restated an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. JPMorgan Chase & Co. lifted their price target on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. William Blair initiated coverage on shares of Cencora in a research note on Tuesday, April 28th. They issued a “market perform” rating on the stock. Finally, Robert W. Baird set a $415.00 price objective on Cencora in a report on Tuesday, January 13th. Twelve research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $398.17.

Key Cencora News

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Management raised FY‑2026 adjusted EPS guidance to a range of $17.65–$17.90 and authorized a $1 billion share repurchase, which supports earnings per share and signals capital return priority. Business Wire: Q2 Results
• Positive Sentiment: Gross margins expanded (around +45 bps) driven by the OneOncology integration and stronger international operating income (double‑digit growth), showing improving mix toward higher‑margin services. QuiverQuant: Q2 Opinions
• Positive Sentiment: Wall Street still carries supportive price targets and some buy/overweight opinions (median target materially above current levels), which could limit downside if execution stabilizes. QuiverQuant: Analyst Targets
• Neutral Sentiment: Revenue grew ~3.8% year‑over‑year to ~$78.4B and adjusted EPS rose versus prior year to $4.75, but both results were below consensus estimates — the topline growth is steady but below investor expectations. Zacks: Q2 Miss
• Negative Sentiment: U.S. Healthcare Solutions showed deceleration: branded‑drug price cuts, lower sales to a large mail‑order client and prior customer losses drove the revenue shortfall and concern about near‑term demand mix. Reuters: U.S. Segment Weakness
• Negative Sentiment: Revenue guidance was below consensus (company issued a lower revenue range vs. Street expectations), amplifying investor concern that growth will remain pressured near term. MarketWatch: Revenue Outlook Cut
• Negative Sentiment: Investors flagged negative operating cash flow, GLP‑1 margin pressure and social‑media chatter about customer losses — issues that can weigh on multiple quarters of performance. QuiverQuant: Investor Concerns
• Negative Sentiment: Notable insider selling (multiple executives sold shares over the past six months), which some market participants view as an additional negative signal amid the miss. QuiverQuant: Insider Trades

Institutional Investors Weigh In On Cencora

A number of institutional investors and hedge funds have recently made changes to their positions in the business. United Bank grew its position in Cencora by 4.5% in the 2nd quarter. United Bank now owns 7,032 shares of the company’s stock worth $2,109,000 after purchasing an additional 305 shares in the last quarter. Nebula Research & Development LLC bought a new position in Cencora in the 2nd quarter valued at $595,000. Treasurer of the State of North Carolina increased its position in shares of Cencora by 7.9% during the 2nd quarter. Treasurer of the State of North Carolina now owns 85,534 shares of the company’s stock valued at $25,647,000 after purchasing an additional 6,244 shares during the last quarter. Diversify Advisory Services LLC raised its stake in shares of Cencora by 94.1% during the 2nd quarter. Diversify Advisory Services LLC now owns 2,585 shares of the company’s stock worth $747,000 after purchasing an additional 1,253 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in shares of Cencora by 26.0% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 73,452 shares of the company’s stock worth $22,025,000 after buying an additional 15,154 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.